|
Oct 1
|
Ascendis Pharma submits sBLA for growth hormone deficiency therapy
|
|
Oct 1
|
High Growth Tech Stocks To Watch In October 2024
|
|
Sep 30
|
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
|
|
Sep 30
|
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
|
|
Sep 4
|
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
|
|
Sep 4
|
Why Ascendis Pharma Stock Tumbled by 11% Today
|
|
Sep 4
|
Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut
|
|
Aug 29
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Aug 28
|
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
|
|
Jul 24
|
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year
|
|
Jun 24
|
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
|
|
Jun 21
|
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
|
|
May 15
|
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
|
|
May 15
|
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|
|
May 14
|
US Equity Markets Close Higher Tuesday as Producer Prices Rise
|
|
May 14
|
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
|
|
May 14
|
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
|
|
May 13
|
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
|
|
May 9
|
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
|
|
May 6
|
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
|